PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Cash & equivalents declining -9.09% while GNPX's grows 17.63%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Below half of GNPX's 17.63%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Other current assets growth 50-75% of GNPX's -52.47%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-10.41%
Below half of GNPX's 3.97%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.27%
Below half GNPX's -24.54%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Below half of GNPX's 6.81%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Below half of GNPX's 4.60%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.64%
Less than half of GNPX's -21.28%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of GNPX's 33.72%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Less than half of GNPX's 12.38%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Less than half of GNPX's 12.38%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
0.5-0.75x GNPX's -6.46%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
Below half GNPX's 2.11%. Michael Burry sees potential underperformance in building shareholder capital.
-10.20%
Below half GNPX's 4.60%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.98%
Higher Total Investments Growth compared to GNPX's zero value, indicating better performance.
-5.39%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
9.19%
Less than half of GNPX's -17.63%. David Dodd sees better deleveraging or stronger cash buildup than competitor.